Prophylactic efficacy of Pegfilgrastim on the risk of febrile pneutropenia treated with Cabazitaxel after Docetaxel-resistant in patients with castration-resistant prostate cancer - PROSPECT study

Kobe City Medical Center General Hospital0 个研究点目标入组 20 人开始时间: 2017年2月9日最近更新: 2023年10月17日

试验速览

暂无简介。

•1.Bone marrow function falls by the previous treatment by radiation. 2.Patients have a history of radiation therapy by Sm^153 or P^32 within eight weeks after registration, or by Sr^89 or Ra^223 within twelve weeks after registration. 3.Patient who have a history of an operation, radiation or chemotherapy within four weeks after registration. 4.Patients with a peripheral nerve obstacle of grade more than 2. 5.Patients with stomatitis of grade more than 2. 6.Patient with active infection that should be administered antibiotic or anti-fungal agent 7.Patients with other cancers in the past for five years except for early cancer that should be cured. 8.Patients with brain metastasis or meningitis carcinomatosa 9.Patients with a history of hypersensitive reaction to docetaxel, polysorbate80, prednisolone, granulocyte colony-stimulating factor. 10.Patients with a history of serious arrhythmia, angina pectoris, hypertension, diabetes mellitus, congestive heart failure or myocardial infarction within six months. Patients general condition remain unstable even with intensive care. 11.Patients with interstitial pneumonia on chest X-ray. 12.Patients that need a blood transfusion within fourteen day after chemotherapy.

发起方